regn5678
mAbexperimentalMulti-specific
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 26, 2019 (NCT03972657)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
CD28 inhibitor
- Glutamate carboxypeptidase IIImmunity, passive
FOLH1 immunity, passive
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06826768 | Phase 1 | May 1, 2025 | Regeneron, University of Texas at Houston |
| NCT06085664 | Phase 1/Phase 2 (Phase 2) | Dec 4, 2023 | University of Texas at Houston |
| NCT03972657 | Phase 1/Phase 2 (Phase 2) | Jun 26, 2019 | Regeneron |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Regeneron | For profit | 2 | 1 | 2 | 2019 |
| University of Texas at Houston | Academic/Hospital | 2 | 2 | 2 | 2023 |
2 organizations
Page 1 / 1